Initial Clinical Experience with (90)Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

Fibroblast activation protein (FAP) is overexpressed in several solid tumors and therefore represents an attractive target for radiotheranostic applications. Recent investigations demonstrated rapid and high uptake of small-molecule inhibitors of FAP ((68)Ga-FAPI-46) for PET imaging. Here, we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferdinandus, Justin, Costa, Pedro Fragoso, Kessler, Lukas, Weber, Manuel, Hirmas, Nader, Kostbade, Karina, Bauer, Sebastian, Schuler, Martin, Ahrens, Marit, Schildhaus, Hans-Ulrich, Rischpler, Christoph, Grafe, Hong, Siveke, Jens T., Herrmann, Ken, Fendler, Wolfgang P., Hamacher, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2022
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051597/
https://www.ncbi.nlm.nih.gov/pubmed/34385340
http://dx.doi.org/10.2967/jnumed.121.262468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051597/
https://www.ncbi.nlm.nih.gov/pubmed/34385340
http://dx.doi.org/10.2967/jnumed.121.262468

Ejemplares similares